C

Carmell Corp
NASDAQ:CTCX

Watchlist Manager
Carmell Corp
NASDAQ:CTCX
Watchlist
Price: 0.1973 USD 1.39%
Market Cap: 5.9m USD

Relative Value

There is not enough data to reliably calculate the relative value of CTCX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CTCX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
14
vs Industry
11
Median 3Y
20.1
Median 5Y
0
Industry
7.9
vs History
vs Industry
8
Median 3Y
-0.3
Median 5Y
-0.9
Industry
24
vs History
vs Industry
Median 3Y
-6.7
Median 5Y
-14.1
Industry
21.6
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-12
Industry
23.7
vs History
vs Industry
68
Median 3Y
-1.5
Median 5Y
1.9
Industry
3.4
vs History
14
vs Industry
11
Median 3Y
19.9
Median 5Y
0
Industry
8.3
vs History
14
vs Industry
7
Median 3Y
21.5
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-19.4
Industry
6.7
vs History
vs Industry
Median 3Y
-5
Median 5Y
-19.1
Industry
7.2
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-14
Industry
8.2
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-13.9
Industry
6.7
vs History
vs Industry
69
Median 3Y
0.6
Median 5Y
1.9
Industry
5.7

Multiples Across Competitors

CTCX Competitors Multiples
Carmell Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Carmell Corp
NASDAQ:CTCX
5.9m USD 181.2 -0.2 -0.5 -0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 794 036.5 -160 618 -195 041.5 -192 815.9
US
Abbvie Inc
NYSE:ABBV
395.9B USD 6.6 168.6 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
170.8B USD 4.7 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
153B USD 5.3 18.9 12.7 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD 9.7 30.8 22.6 23.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.7 -531.9 -579.2 -563.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD 5.5 17.2 16.3 18.5
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.8 13.3 16.5
NL
argenx SE
XBRU:ARGX
46.3B EUR 15.1 35.5 61.4 63.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.4B USD 16.9 1 248.3 164.2 199.1
P/S Multiple
Revenue Growth P/S to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average P/S: 3 072 397.3
181.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 794 036.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
10%
1
US
E
Epizyme Inc
F:EPE
2 084.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.1
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
46%
0.4
P/E Multiple
Earnings Growth PEG
US
C
Carmell Corp
NASDAQ:CTCX
Average P/E: 195.4
Negative Multiple: -0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 618 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.9
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.8
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
9%
1.9
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
35.5
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 248.3
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average EV/EBITDA: 40.6
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
11%
1.5
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
61.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
164.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
Carmell Corp
NASDAQ:CTCX
Average EV/EBIT: 46.8
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
63.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
199.1
N/A N/A